Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
| ▸ | METAP2 | P50579 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | PPM1D | O15297 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984985 | 0.89 | EPHX2 (0.56) | EPHX2EPHX1METAP2MEN1KMT2A | |
| SCHEMBL12022079 | 0.87 | EPHX2 (0.54) | EPHX2EPHX1METAP2MEN1KMT2A | |
| SCHEMBL19350499 | 0.87 | EPHX2 (0.54) | EPHX2EPHX1METAP2MEN1KMT2A | |
| SCHEMBL12069065 | 0.85 | EPHX2 (0.52) | EPHX2EPHX1METAP2MEN1KMT2A | |
| SCHEMBL7349858 | 0.85 | METAP2 (0.68) | EPHX2EPHX1METAP2MEN1KMT2A | |
| SCHEMBL25858386 | 0.82 | METAP2 (0.51) | METAP2MEN1KMT2ALMNAMETAP1 | |
| SCHEMBL15200378 | 0.78 | RAB9A (0.48) | METAP2NPC1RAB9APOLBMETAP1 | |
| SCHEMBL14984991 | 0.77 | NPC1 (0.53) | METAP2MEN1KMT2ATSHRNPC1 | |
| SCHEMBL6488852 | 0.77 | METAP2 (0.72) | EPHX2EPHX1METAP2MEN1KMT2A | |
| SCHEMBL15199424 | 0.77 | NPC1 (0.46) | METAP2TSHRNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155545-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155545-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | EPHX2 2620/4885EPHX1 3359/4885METAP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.